Chase Investment Counsel’s BioAtla BCAB Stock Holding History

Chase Investment Counsel’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,535	Closed	-$263K	–	127
2024 Q1	$263K	Buy	+1,535	New	+$191K	0.1%	126

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

SAM

Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Chase Investment Counsel's BCAB Position: Q2 2024 in Review

Chase Investment Counsel sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 1,535 shares — an estimated $263K sold.

Chase Investment Counsel first reported a position in BCAB in Q1 2024 and held it in 1 quarter. The position peaked at $263K in Q1 2024. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

Chase Investment Counsel reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
Chase Investment Counsel sold 1,535 BioAtla shares in Q2 2024, an estimated $263K.
Chase Investment Counsel first reported a position in BioAtla in Q1 2024 and held it in 1 quarter.
Chase Investment Counsel's BioAtla position peaked at $263K in Q1 2024.
80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Chase Investment Counsel's 13F filing for Q2 2024, filed 2 Aug 2024.